RxDoctor Payments Data

Nelson Usry, MD

Family Medicine · Saint Louis, MONPI 1689796294

Payments from drug & device makers

$4,494in general payments, 2019–2025

Across 238 payments — averaging $18.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$680
  • Novo Nordisk$401
  • Lilly USA, LLC$399
  • Pfizer$346
  • Boehringer Ingelheim$234
  • GSK$184
  • plus $2K from 44 others

What the payments were for

  • Food & beverage$4,494100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,494 in reported general payments places this provider in the 85th percentile of 2,203 family medicine providers in Missouri.

See all family medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$63,534
Medicare patients
178
Services billed
2,194

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide79$91,899
EliquisApixaban54$73,135
JardianceEmpagliflozin84$72,772
XareltoRivaroxaban54$59,268
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$25,788
Breo ElliptaFluticasone/Vilanterol33$22,968
OzempicSemaglutide18$17,377
FarxigaDapagliflozin Propanediol14$16,206
JanumetSitagliptin Phos/Metformin Hcl16$10,279
MyrbetriqMirabegron15$8,462
SymbicortBudesonide/Formoterol Fumarate17$6,861
AbrysvoRsv Vacc, Pref A And Pref B/Pf29$6,698
ArexvyRsvpref3 Antigen/As01e/Pf20$4,745
Atorvastatin Calcium532$4,515
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$4,370

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$399$91,89979 claims
PfizerEliquis, Abrysvo$346$79,83383 claims
Boehringer IngelheimJardiance$234$72,77284 claims
Johnson & JohnsonXarelto$176$59,26854 claims
GSKTrelegy Ellipta, Breo Ellipta, Arexvy$184$53,50187 claims
AstraZenecaFarxiga, Symbicort$137$23,06731 claims
Novo NordiskOzempic$401$17,37718 claims
MerckJanumet$56$10,27916 claims
Astellas Pharma US IncMyrbetriq$80$8,46215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,203 family medicine providers in Missouri.

Other family medicine in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →